Cargando…
Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample
BACKGROUND: We sought to determine whether clinical response or tolerance to the Selective Serotonin Reuptake Inhibitor (SSRI) citalopram is associated with genetic polymorphisms in potentially relevant pharmacokinetic enzymes. METHODOLOGY: We used a two-stage case-control study design in which we s...
Autores principales: | Peters, Eric J., Slager, Susan L., Kraft, Jeffrey B., Jenkins, Greg D., Reinalda, Megan S., McGrath, Patrick J., Hamilton, Steven P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268970/ https://www.ncbi.nlm.nih.gov/pubmed/18382661 http://dx.doi.org/10.1371/journal.pone.0001872 |
Ejemplares similares
-
Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR(*)D
por: Adkins, D E, et al.
Publicado: (2012) -
Maternal Pharmacokinetics and Fetal Disposition of
(±)-Citalopram during Mouse Pregnancy
por: Velasquez, Juan C., et al.
Publicado: (2016) -
Novel loci for major depression identified by genome-wide association study of STAR*D and meta-analysis of three studies
por: Shyn, SI, et al.
Publicado: (2009) -
Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR*D study
por: Chiarotti, F, et al.
Publicado: (2017) -
Rise of escitalopram and the fall of citalopram
por: Cavanah, Luke R., et al.
Publicado: (2023)